
Overview
Naturalantibody is a company that streamlines antibody discovery using a comprehensive database that integrates antibody data and employs machine learning solutions for predicting developability issues. It offers tools for structural modeling, paratope prediction, and antibody-antigen docking analysis, along with support for library construction and data visualization. Additionally, it provides free cloud and on-premises versions of its platform for users to manage and analyze their antibody-related data.
- ul. Podole 60, 30-394 Kraków
Financials
Revenue history (in k)
Filing timeliness
1 of 5 financial statements was filed late (for 2021, 89 days late). All were audited by a statutory auditor.
- 202503/07/2026
- 202401/07/2025
- 202305/07/2024
- 202210/07/2023
- 202112/10/2022
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Antibody discovery platform
- Antibody databases
- Bioinformatics software
- Antibody sequence analysis
- Mutation prediction
Websites
- naturalantibody.comAI Computational Solutions for Antibody Engineering – NaturalAntibodyGoogle Tag Manager
Job offers
The company has its own careers page: naturalantibody.com/careers.
Authorized Representatives
Manner of representation
The company shall be represented as follows: a) in the case of a one-person management board, the company shall be represented by the sole member of the management board; b) in the case of a multi-member management board, the company shall be represented by each member of the management board independently; c) in the case of a multi-member management board and the appointment of a Vice-President of the Management Board for financial matters, the company shall be represented by two members of the management board acting jointly, provided that in every case the joint action of the Vice-President of the Management Board for financial matters shall be required.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2020-12-10.
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| May 25, 2023 | Shareholders' meeting convened | |
| Sep 8, 2022 | Shareholders' meeting convened |
Public aid
18 public aid cases recorded, with a total value of $5,544,696.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 29, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Krakowski Park Technologiczny sp. z o.o. | |
| May 25, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Dec 19, 2025 | Aid for SME participation in trade fairs | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
4 projects co-financed from European Funds recorded, with total EU co-financing of $5,530,711.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-01-01 | Strengthening the export potential of NATURALANTIBODY SPÓŁKA AKCYJNA through participation in international events. | $405.9K$405,873 | European Funds for a Modern Economy | |
| 2024-11-01 | Development of a technology for extracting data from scientific literature using large language models to discover therapeutic antibodies | $853.7K$853,708 | European Funds for Western Pomerania 2021-2027 | |
| 2024-04-01 | Development of Specitope technology for bioinformatic prediction of B-cell-specific epitopes, enabling the in silico identification of therapeutic antibody candidates | $2.4M$2,431,856 | European Funds for Małopolska 2021-2027 |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Datawalk S.A. | $10,256,152.69 | datawalk.pl | ||
| Dotdata Poland sp. z o.o. | $4,074,402.77 | dotdata.com | ||
| Prointegra S.A. | $3,448,932.47 | prointegra.com.pl | ||
| Evidence Prime sp. z o.o. | $2,703,278.11 | evidenceprime.com | ||
| Diagnostyka Digital Hub sp. z o.o. | $2,669,153.37 | diagnostyka.digital | ||
| Creatoriq Europe sp. z o.o. | $2,570,504.34 | creatoriq.com | ||
| Data4cure Poland sp. z o.o. | $1,824,382.17 | data4cure.com | ||
| Algolytics Technologies sp. z o.o. | $1,599,468.50 | algolytics.com | ||
| Palturai sp. z o.o. | $1,006,781.72 | palturai.com | ||
| Iamip Technology sp. z o.o. | $763,930.26 | iamip.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-01-15 | Address change (Al. Piastów 22, 71-064, Szczecin → Ul. Niemierzyńska 17a/Bud.f1/110, 71-441, Szczecin) | |
| 2025-01-15 | Share capital increase (132,979.00 PLN → 136,613.00 PLN) | |
| 2024-08-07 | Share capital increase (126,591.00 PLN → 132,979.00 PLN) | |
| 2023-11-24 | Share capital increase (108,696.00 PLN → 126,591.00 PLN) | |
| 2021-10-07 | Share capital increase (100,000.00 PLN → 108,696.00 PLN) |
FAQ
Last updated: 2026-09-03
